BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 21559015)

  • 1. A novel fully human antitumour immunoRNase targeting ErbB2-positive tumours.
    Borriello M; Laccetti P; Terrazzano G; D'Alessio G; De Lorenzo C
    Br J Cancer; 2011 May; 104(11):1716-23. PubMed ID: 21559015
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A novel fully human antitumor immunoRNase resistant to the RNase inhibitor.
    Riccio G; D'Avino C; Raines RT; De Lorenzo C
    Protein Eng Des Sel; 2013 Mar; 26(3):243-8. PubMed ID: 23232187
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of a second-generation human anti-ErbB2 ImmunoRNase on trastuzumab-resistant tumors and cardiac cells.
    D'Avino C; Paciello R; Riccio G; Coppola C; Laccetti P; Maurea N; Raines RT; De Lorenzo C
    Protein Eng Des Sel; 2014 Mar; 27(3):83-8. PubMed ID: 24421342
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combinatorial experimental protocols for Erbicin-derived immunoagents and Herceptin.
    De Lorenzo C; Troise F; Cafaro V; D'Alessio G
    Br J Cancer; 2007 Nov; 97(10):1354-60. PubMed ID: 17923870
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Biological properties of a human compact anti-ErbB2 antibody.
    De Lorenzo C; Cozzolino R; Carpentieri A; Pucci P; Laccetti P; D'Alessio G
    Carcinogenesis; 2005 Nov; 26(11):1890-5. PubMed ID: 15930029
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Differential binding of human immunoagents and Herceptin to the ErbB2 receptor.
    Troise F; Cafaro V; Giancola C; D'Alessio G; De Lorenzo C
    FEBS J; 2008 Oct; 275(20):4967-79. PubMed ID: 18795950
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intracellular route and mechanism of action of ERB-hRNase, a human anti-ErbB2 anticancer immunoagent.
    De Lorenzo C; Di Malta C; Calì G; Troise F; Nitsch L; D'Alessio G
    FEBS Lett; 2007 Jan; 581(2):296-300. PubMed ID: 17208233
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A novel human antitumor dimeric immunoRNase.
    Riccio G; Borriello M; D'Alessio G; De Lorenzo C
    J Immunother; 2008 Jun; 31(5):440-5. PubMed ID: 18463541
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of a human compact anti-ErbB2 antibody on gastric cancer.
    Fedele C; Carvalho S; Riccio G; Paciello R; Laccetti P; Schmitt F; De Lorenzo C
    Gastric Cancer; 2014 Jan; 17(1):107-15. PubMed ID: 23460348
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Two novel human anti-ErbB2 immunoagents are active on trastuzumab-resistant tumours.
    Gelardi T; Damiano V; Rosa R; Bianco R; Cozzolino R; Tortora G; Laccetti P; D'Alessio G; De Lorenzo C
    Br J Cancer; 2010 Feb; 102(3):513-9. PubMed ID: 20051960
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A new RNase-based immunoconjugate selectively cytotoxic for ErbB2-overexpressing cells.
    De Lorenzo C; Nigro A; Piccoli R; D'Alessio G
    FEBS Lett; 2002 Apr; 516(1-3):208-12. PubMed ID: 11959134
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of a human compact anti-ErbB2 antibody on prostate cancer.
    Malara AE; Fedele C; Aloj L; Arra C; Laccetti P; D'Alessio G; De Lorenzo C
    Oncol Rep; 2012 Jul; 28(1):297-302. PubMed ID: 22505344
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Human anti-ErbB2 immunoagents--immunoRNases and compact antibodies.
    De Lorenzo C; D'Alessio G
    FEBS J; 2009 Mar; 276(6):1527-35. PubMed ID: 19220462
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mechanisms of cardiotoxicity associated with ErbB2 inhibitors.
    Fedele C; Riccio G; Malara AE; D'Alessio G; De Lorenzo C
    Breast Cancer Res Treat; 2012 Jul; 134(2):595-602. PubMed ID: 22674190
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A novel fully human anti-NCL immunoRNase for triple-negative breast cancer therapy.
    D'Avino C; Palmieri D; Braddom A; Zanesi N; James C; Cole S; Salvatore F; Croce CM; De Lorenzo C
    Oncotarget; 2016 Dec; 7(52):87016-87030. PubMed ID: 27894092
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A fully human antitumor immunoRNase selective for ErbB-2-positive carcinomas.
    De Lorenzo C; Arciello A; Cozzolino R; Palmer DB; Laccetti P; Piccoli R; D'Alessio G
    Cancer Res; 2004 Jul; 64(14):4870-4. PubMed ID: 15256457
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A novel ErbB2 epitope targeted by human antitumor immunoagents.
    Troise F; Monti M; Merlino A; Cozzolino F; Fedele C; Russo Krauss I; Sica F; Pucci P; D'Alessio G; De Lorenzo C
    FEBS J; 2011 Apr; 278(7):1156-66. PubMed ID: 21288302
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A human, compact, fully functional anti-ErbB2 antibody as a novel antitumour agent.
    De Lorenzo C; Tedesco A; Terrazzano G; Cozzolino R; Laccetti P; Piccoli R; D'Alessio G
    Br J Cancer; 2004 Sep; 91(6):1200-4. PubMed ID: 15305184
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antitumor activity and toxicity of anti-HER2 immunoRNase scFv 4D5-dibarnase in mice bearing human breast cancer xenografts.
    Balandin TG; Edelweiss E; Andronova NV; Treshalina EM; Sapozhnikov AM; Deyev SM
    Invest New Drugs; 2011 Feb; 29(1):22-32. PubMed ID: 19789841
    [TBL] [Abstract][Full Text] [Related]  

  • 20. T-cell Activating Tribodies as a Novel Approach for Efficient Killing of ErbB2-positive Cancer Cells.
    Riccio G; Ricardo AR; Passariello M; Saraiva K; Rubino V; Cunnah P; Mertens N; De Lorenzo C
    J Immunother; 2019 Jan; 42(1):1-10. PubMed ID: 30520849
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.